U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07767487) titled 'A Study of LY4226695 in Healthy Participants' on Aug. 12.
Brief Summary: The main purpose of this study is to assess how well LY4226695 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant in Parts A & D, the study will last about 64 days and will include a stay in the Clinical Research Unit (CRU) lasting at most 7 days. For each participant in Parts B & C, the study will last about 92 days and will include 5 stays in the CRU with each visit lasting at most 7 days.
Study S...